Latest Nasdaq News

Resolution Minerals has earned FAST-41 transparency status for its Golden Gate Project in Idaho, marking its second such designation and positioning the company as a key player in U.S. critical minerals supply chain development.

Immuron Limited reported a 6% increase in FY26 sales to AUD 7.7 million, driven by strong gains in Canada and the US despite mixed Australian performance. Marketing initiatives and retail expansion underpin growth.

Immutep’s INSIGHT-003 trial shows promising overall survival in first-line non-squamous NSCLC, yet the Phase III TACTI-004 trial was discontinued following a futility analysis. Ongoing root cause investigations aim to clarify the divergent outcomes.

CLINUVEL Pharmaceuticals secures Canadian marketing approval for SCENESSE®, expanding access to the only approved systemic photoprotective treatment for erythropoietic protoporphyria (EPP).

Chilwa Minerals has lodged a Form F-1 registration with the US SEC, aiming to raise capital through a Nasdaq listing of American Depositary Shares while maintaining its ASX presence.

Mesoblast Limited’s Ryoncil® posted US$36 million in Q4 revenue, driving a full-year total of US$115 million, exceeding initial forecasts. The FDA-approved stem cell therapy for pediatric graft-versus-host disease shows robust uptake across US pediatric centres.

Elevra Lithium’s North American Lithium operation posted a 15% production increase in June 2026, setting a monthly record in May. While sales prices lagged behind spot rates due to legacy contracts, the company expects future pricing to improve as these contracts conclude.

IperionX has secured approximately US$50 million through a public offering of American Depositary Shares, targeting the scale-up of its titanium production and expansion of key US facilities.

Ioneer has signed non-binding MOUs with Korea’s KIND and Hyundai Engineering, edging closer to a Final Investment Decision for its Rhyolite Ridge lithium-boron project in Nevada.

Alterity Therapeutics has secured official FDA confirmation that a single pivotal Phase 3 trial, backed by prior Phase 2 data, can support approval of ATH434 for Multiple System Atrophy. Trial initiation remains on track for late 2026.

European Lithium and Critical Metals Corp. have amended their merger agreement, introducing a sale facility option for small shareholders and switching to direct share issuance, aiming for scheme implementation in October 2026.

IperionX has bolstered its U.S. critical minerals footprint by acquiring the Camden assets adjacent to its Titan Project, unveiling surface stockpiles with up to 23% Total Heavy Minerals, up to 10 times Titan’s average grade, and established infrastructure that could accelerate domestic supply chains for titanium and rare earths.